+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis



Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis



Frontiers in Cellular and Infection Microbiology 8: 181



The Leishmania parasite resides and replicates within host macrophages during visceral leishmaniasis (VL). This study aimed to evaluate neopterin, a marker of macrophage activation, as possible pharmacodynamic biomarker to monitor VL treatment response and to predict long-term clinical relapse of VL. Following informed consent, 497 plasma samples were collected from East-African VL patients receiving a 28-day miltefosine monotherapy (48 patients) or 11-day combination therapy of miltefosine and liposomal amphotericin B (L-AMB, 48 patients). Neopterin was quantified with ELISA. Values are reported as median (inter-quartile range). Baseline neopterin concentrations were elevated in all VL patients at 98.8 (63.9-135) nmol/L compared to reported levels for healthy controls (<10 nmol/L). During the first treatment week, concentrations remained stable in monotherapy patients (p = 0.807), but decreased two-fold compared to baseline in the combination therapy patients (p < 0.01). In the combination therapy arm, neopterin concentrations increased significantly 1 day after L-AMB infusion compared to baseline for cured patients [137 (98.5-197) nmol/L, p < 0.01], but not for relapsing patients [84.4 (68.9-106) nmol/L, p = 0.96]. The neopterin parameter with the highest predictive power for VL relapse was a higher than 8% neopterin concentration increase between end of treatment and day 60 follow-up (ROC AUC 0.84), with a 93% sensitivity and 65% specificity. In conclusion, the identified neopterin parameter could be a potentially useful surrogate endpoint to identify patients in clinical trials at risk of relapse earlier during follow-up, possibly in a panel of biomarkers to increase its specificity.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066432083

Download citation: RISBibTeXText

PMID: 29911074

DOI: 10.3389/fcimb.2018.00181


Related references

Identification and Functional Validation of a Biomarker for the Diagnosis of Miltefosine Relapse during Visceral Leishmaniasis. American Journal of Tropical Medicine and Hygiene 98(2): 492-496, 2017

Identification and functional validation of a biomarker for the diagnosis of miltefosine relapse during visceral leishmaniasis. International Journal of Infectious Diseases 45: 74-75, 2016

IgG1 as a potential biomarker of post-chemotherapeutic relapse in visceral leishmaniasis, and adaptation to a rapid diagnostic test. Plos Neglected Tropical Diseases 8(10): E3273, 2015

Neopterin in autoimmune neurological diseases a marker of macrophage activation. Journal of Neuroimmunology 16(1): 142, 1987

Recombinant prohibitin protein of Leishmania infantum acts as a vaccine candidate and diagnostic marker against visceral leishmaniasis. Cellular Immunology 323: 59-69, 2017

Macrophage activation syndrome and autoimmunity due to visceral leishmaniasis. Archives de Pediatrie 22(4): 397-400, 2015

Inappropriate macrophage activation syndrome associated with visceral leishmaniasis in an infant. Tunisie Medicale 77(12): 648-650, 1999

Syndrome of inappropriate macrophage activation associated with infantile visceral leishmaniasis. La Tunisie Medicale 77(12): 648-650, 2000

Severe macrophage activation syndrome following visceral leishmaniasis in a child. Medecine et Sante Tropicales 24(2): 221-223, 2015

Genome-Wide Scan for Visceral Leishmaniasis in Mixed-Breed Dogs Identifies Candidate Genes Involved in T Helper Cells and Macrophage Signaling. Plos One 10(9): E0136749, 2016

Amphotericin: a candidate for first-line treatment of visceral leishmaniasis?. WHO Drug Information 9(4): 215-216, 1995

Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient. American Journal of Tropical Medicine and Hygiene 80(4): 580-582, 2009

Evaluation of ex vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine. American Journal of Tropical Medicine and Hygiene 82(5): 808-813, 2010

Lymphoproliferative response after stimulation with soluble leishmania antigen (SLA) as a predictor of visceral leishmaniasis (VL) relapse in HIV+ patients. Acta Tropica 164: 345-351, 2016

Visceral Leishmaniasis Associated with Macrophage Activation Syndrome and Diffuse Alveolar Hemorrhage in a Lupus Patient. Acta Medica Portuguesa 31(10): 593-596, 2018